Hybrid Capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens

Cancer Cytopathology

Volumn 117, Issue 5, 2009, Pages 318-325

  Siddiqi, Anwer ^a   Spataro, Michael ^b   McIntire, Holly ^a   Akhtar, Israh ^a   Baliga, Mithra ^a   Flowers, Rhyne ^a   Lin, E ^c   Guo, Ming ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Human papillomavirus; Hybrid Capture 2; SurePath; ThinPrep

Indexed keywords

VIRUS DNA;

ALPHAPAPILLOMAVIRUS; ARTICLE; BIOPSY; COMPARATIVE STUDY; EVALUATION; FEMALE; FOLLOW UP; GENETICS; HISTOLOGY; HUMAN; METHODOLOGY; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; PAPILLOMAVIRUS INFECTIONS; VAGINAL SMEARS; VIROLOGY;

EID: 73349142020     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20043     Document Type: Article

References (14)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796-802.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342-350.
4. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346-355.
5. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004; 103: 304-309.
6. Castle PE, Wheeler CM, Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004; 122: 238-245.
7. Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293-299.
8. Ko V, Tambouret RH, Kuebler DL, et al. Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer. 2006; 108: 468-474.
9. Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol. 2007; 16: 125-129.
10. Arbyn M, Sasieni P, Meijer CJ, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24(suppl 3):S3/78-S3/89.
11. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; (31): 3-13.
12. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005; 191: 1808-1816.
13. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-819.
14. Alsharif M, McKeon DM, Gulbahce HE, et al. Unsatisfactory SurePath liquid-based Papanicolaou tests: causes and significance. Cancer Cytopathol. 2009; 117: 15-26.